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ABSTRACT. The metalloenzyme peptide deformylase (PDF) catalyzes the 
elimination of the N-formyl group from N-terminal methionine upon translation, 
which is crucial for protein synthesis, growth, and survival of bacteria. In this 
context, we aim to identify potent derivatives of the known mycobacterial PDF 
(mPDF) inhibitors having better pharmacological properties than their parent 
compounds. Initially, BB-83698, Galardin, and LBK-611 known mPDF inhibitors 
were selected based on their binding affinity for mPDF using iGEMDOCK. Analogs 
of these three inhibitors were prepared. Further, the analogs were screened based on 
their oral bioavailability, pharmacokinetics properties, drug likeliness and binding 
energy. The post-screening analysis reveals that the analog, 
(2R)-N’-hydroxy-N-[(2S)-3-(5H-indol-3-yl)-1-oxopropan-2-yl]-2-(2-methylpropyl) 
butanediamide (CID5288446) of galardin interacts with residues GLN56, LEU107, 
HIS148, GLU149, and HIS152 near the vicinity of the active site (H132EXXH136) of 
mPDF protein with higher affinity as compared to its parent compound galardin. 
The prediction tool based upon structure-activity relationship reveals that the analog 
CID5288446 showed similar metalloproteinase activity with lesser toxic effects 
when compared to its parent compound galardin. 
Keywords: Mycobacterial Peptide Deformylase (mPDF); structure-based virtual 
screening; fitness score; pharmacokinetics properties; drug likeliness; Inhibitors. 
 
 
1. Introduction. Tuberculosis (TB) is an infectious disease that has afflicted humans since the Neolithic 
period. Mycobacterium tuberculosis (MTB) is a pathogenic bacteria belonging to the genus Mycobacterium 
and is the principal agent responsible for maximum cases of Tuberculosis (TB) [1]. The advent of multi-drug 
resistant (MDR) strains of MTB provides a real challenge to successfully treat tuberculosis infection. There 
were around 190 000 deaths from MDR-TB and roughly 480 000 new cases of MDR-TB worldwide in the 
year 2014 [2]. In order to address this problem, the identification of novel antibiotic against drug-resistant 
strains of MTB is crucial to ensure the future success of therapeutics against MTB. Recently, PDF a 
metalloenzyme crucial for deformylation and maturation of bacterial protein have emerged as a potential 
target to develop novel antimycobacterial agents with a new mode of action [3, 4, 5]. Catalytic removal of the 
N-formyl group from N-terminal methionine upon translation is essential for the growth and viability of MTB 
[6, 7]. Using rationally designed screening protocols many novel classes of inhibitors specific to PDF have 
been identified namely BB-3497 and actinonin [8, 9]. Even many of the derivatives of actinonin namely VIC- 
104959 (LBM 415) and BB-83698  have progressed on to phase II and III trials against clinical strains of 
Haemophilus influenza, Enterococci, Staphylococci and Streptococci [10, 11, 12, 13]. Even though quite a 
few new anti-PDF drugs have reached to clinical trials, but their usage against mycobacterial PDF is difficult 
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to predict. Therefore, there is an urgency of screening novel derivatives of potent PDF inhibitors with 
improved pharmacokinetic and binding properties against mPDF protein. In this context, we were able to 
screen an analog of a well-known mPDF inhibitors and evaluated its` affinity for mPDF. Our in silico study of 
mPDF inhibitors will certainly add on to the list of the probable lead compound against mPDF protein and 
make sure that the pipeline of novel lead compounds against mPDF protein continues. 
 
2. Methods.  
Virtual Screening using iGEMDOCK: The docking tool iGEMDOCK v2.0 was used to perform rapid 
virtual screenings of the mPDF inhibitors compounds against mPDF protein [14, 15, 16] using the crystal 
structure of MTB peptide deformylase [4]. The following four major steps are involved in virtual screening 
using iGEMDOCK: (1) retrieval of target protein structure; (2) preparing compound library; (2) Preparation 
of binding site; (3) protein-ligand docking and (4) Docked poses/post-screening analysis. 
Retrieval and preparation of energy minimized structure of target protein: The crystal structure of MTB 
peptide deformylase with PDB ID 3E3U (resolution 1.56 Å) with an inhibitor was retrieved from Research 
Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) (http://www.rcsb.org/pdb/home/
home.do). The ready to dock minimized structure of PDF protein was prepared using the Dock Prep tool of 
Chimera 1.10.2. 
Ligand preparation: The 3D structural files of seven known mPDF inhibitors namely actonin, BB-3497, 
galardin, LBK-611, N-alkyl urea hydroxamic acids, VRC-3324 and VRC-3325 and their corresponding 
analogs were downloaded from PubChem database (https://pubchem.ncbi.nlm.nih.gov/compound/). The 
structures downloaded were in .sdf format. OpenBabel (http://openbabel.org/wiki/Main_Page) software was 
used to convert the .sdf files to .mol2 format since iGEMDOCK docking tool needs structural files in .mol2 
format for executing molecular docking calculations. Ready to use dock prep structures of PDF inhibitors 
were prepared using Chimera 1.10. 
Ligand Binding Site Preparation: The mPDF protein in complex with inhibitor was downloaded in .pdb 
format from RCSB PDB (PDB ID 3E3U). The binding region of the bounded inhibitor was defined as the 
binding site for virtual screening. The bounded inhibitor was defined as the center of the binding domain and 
the size of the binding position was set to a default value of 8 Å. 
Ligand-protein docking of known PDF inhibitors: Standard docking protocol of iGEMDOCK v2.0 was 
used to screen inhibitor compounds having a higher affinity for mPDF protein. A population size of 200 with 
70 generation and two solutions for each generation was set for molecular docking studies. Top three mPDF 
inhibitors were selected based on their affinity for the ligand binding domain of the crystal structure of the 
mPDF protein. 
Analog preparation and virtual screening: A library of analogs of top three mPDF inhibitors screened 
based on their affinity for mPDF protein was retrieved from PubChem, dock prepared using chimera 1.10.2 
and screened against the crystal structure of the mPDF protein using the standard docking procedure of 
iGEMDOCK. The top ten analogs selected based on their affinity for the targeted ligand binding domain of 
mPDF protein were further checked for their pharmacological and drug-likeliness properties.  
Drug-Likeness and Pharmacological Analysis of screened analogs: The physiochemical descriptors of the 
selected ten ligands were estimated for oral drug availability, drug-likeness and pharmacokinetics properties 
of the screened ligands using SwissADME (http://www.swissadme.ch/index.php). On the basis of binding 
affinity, drug-likeliness, and ADME properties, eight ligands were selected for very accurate docking studies. 
Molecular docking and post-dock interaction studies of screened ligand and its parental compound: 
The screened drug-like lead analog molecule and its parent compound were subjected to the very slow 
docking (accurate docking) procedure of iGEMDOCK. Once molecular docking was completed, 
protein-ligand interaction profile consisting of Van der Waal’s (V), hydrogen-bonding (H) and electrostatic 
(E) was generated. Based on these profiles the compounds are compared using the energy-based scoring 
function iGEMDOCK [16].  
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Visualization of the interacting residues: The 2-D representation of the interacting residues of the docked 
complexes was generated by LIGPLOT PLUS program [17]. The pictorial representation was helpful in 
determining the interacting functional groups of the novel drug-like lead molecule with the target protein. 
Prediction of biological activity and toxicity of the screened drug-like molecule and its parental 
compound: PASS (Prediction of Activity Spectra for Substances) software based on the structure-activity 
relationship [18, 19] was used to predict the biological activity and potential toxic effects of both the screened 
drug-like ligand and its parental molecule.  
 
3. Results and Dicussion 
Virtual screening analysis: Based upon their total binding energy (affinity) for mPDF protein top three PDF 
inhibitors namely BB-83698 (-143.679 kcal/mol), Galardin (-133.186 kcal/mol) and LBK-611 (128.687 
kcal/mol) were selected using standard screening protocol of iGEMDOCK and tabulated in Table 1. Further, 
ten best derivatives (analogs) derived from parent inhibitor molecules (BB-83698, Galardin, and LBK-611) 
were chosen based on their affinity (binding energy) for mPDF protein and are listed in Table 2. It can be 
observed that derivatives CID 20752846 and CID 5288446 of BB-83698 and Galardin, respectively showed a 
better binding affinity for mPDF protein when compared to other derivatives of same or other parent inhibitor 
molecules. 
 
Table 1: Binding Energies for the known mPDF inhibitors against the crystal structure of mPDF using the 
standard docking protocol of iGEMDOCK 
 
Sl. No.  mPDF inhibitors  Total Energy VDW HBond Elec 
1 BB-83698 -139.679 -123.232 -16.447 0 
2 Galardin -127.186 -107.735 -19.4516 0 
3 LBK611 -125.687 -94.0976 -33.5896 0 
4 Actinonin -124.614 -92.9471 -31.6666 0 
5 LBM 415 -112.225 -93.0621 -19.1625 0 
6 VRC-3324  -111.277 -96.723 -14.5543 0 
7 VRC-3375  -119.256 -90.4762 -28.7797 0 
8 N-alkyl urea hydroxamic acids -110.285 -90.108 -20.177 0 
9 BB-3497 -102.737 -95.9264 -6.81028 0 
 
 
Table 2: Binding Energies for the ten best analogs of mPDF inhibitors docked against the crystal structure of 
mPDF protein 
 
Sl. No. Analog of 
mPDF inhibitors 
Parent connectivity 
(mPDF inhibitors) 
Total Energy VDW HBond Elec 
1 CID 20752846 BB-83698 -140.526 -114.41 -26.1165 0 
2 CID 5288446 Galardin -136.663 -102.282 -34.3812 0 
3 CID 20752877 BB-83698 -135.494 -112.384 -23.1102 0 
4 CID 23520197 LBK-611 -132.242 -103.057 -29.1846 0 
5 CID 74332344 LBK-611 -129.252 -105.001 -24.2513 0 
6 CID 10346022 BB-83698 -127.805 -119.347 -8.45779 0 
7 CID 510181 BB-83698 -127.12 -101.409 -25.7106 0 
8 CID 58763319 LBK-611 -122.284 -103.303 -18.9816 0 
9 CID 86706411 LBK-611 -121.59 -88.4755 -33.1149 0 
10 CID 74332343 LBK-611 -121.21 -97.4957 -23.7147 0 
 
Oral bioavailability and drug-likeness studies: The physiochemical properties showing the oral 
bioavailability and drug-likeness of the ten best-screened ligands were evaluated using SwissADME server 
and are tabulated in Table 3. 
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Table 3: The physiochemical properties depicting the oral bioavailability and drug-likeliness of the ten 
best-fitted analogs of mPDF inhibitors 
 
Sl. 
No 
Molecule MW 
 
 
Fraction 
Csp3 
 
Rotatable 
bonds 
 
TPSA 
 
XLOGP3 
 
ESOL 
Log S 
 
Lipinski 
violations 
 
Drug-Likeness 
1 CID 
23520197 
395.4 
 
0.53 
 
11 
 
119.0 
 
1.4 
 
-2.6 
 
None Yes 
2 CID 
74332344 
363.4 
 
0.59 
 
11 
 
115.7 
 
0.37 
 
-1.8 
 
None Yes 
3 CID 
5288446 
388.5 0.5 
 
8 
 
119.9 
 
0.24 
 
-1.6 
 
None Yes 
4  CID 
58763319 
376.5 
 
0.58 
 
11 
 
102.8 
 
1.74 
 
-2.7 
 
None Yes 
5 CID 
86706411 
387.4 
 
0.53 
 
10 
 
124.0 
 
0.68 
 
-2.2 
 
None Yes 
6 CID 
74332343 
363.4 0.59 
 
11 
 
115.7 
 
0.31 
 
-1.7 
 
None Yes 
7 CID 
20752846 
536.71 0.58 13 93.19 4.93 -5.61 1 Yes 
8 CID 
20752877 
559.7 0.66 15 122.73 3.51 -4.64 1 Yes  
9 CID 
10346022 
504.62 0.65 14 111.65 2.91 -4 1 Yes  
10 CID 
510181 
493.66 0.75 13 134.32 2.75 -3.88 None Yes 
 
Oral bioavailability of the ligands was evaluated based on the threshold value of certain physiochemical 
descriptors namely Lipophilicity (-0.7 <XLOGP3 < +5.0), Size (150 g/mol < MV < 500 g/mol), Polarity (20 
Å2 < TPSA < 130 Å2), Insolubility (0 < Log S (ESOL) < 6), Instauration (0.25 < Fraction Csp3 < 1) and 
Flexibility (0 < Num. rotatable bonds < 9) of the SwissADME server. It can be observed fromTable 3 that all 
the chemical analog molecules except CID 5288446 show a violation in the number of rotatable bonds (> 10). 
Moreover, chemical analogs CID 20752846, CID 20752877 and CID 10346022 show an additional violation 
of molecular mass (> 500g/mol). While the chemical analog CID 10346022 shows a violation in molecular 
mass (> 500 g/mol), a number of rotatable bonds (> 10) and polarity (Total Polar Surface Area (TPSA) > 130 
Å2). Therefore in this background, we can predict that the chemical analog CID 5288446 which is a 
derivative of galardin shows better oral bioavailability properties than the other analog molecules. 
Additionally, druglikeness of the chemical analogs was also evaluated using the Lipinski’s rule of five (RO5) 
[20]. As per RO5, a chemical compound to be orally active in human should follow minimum three criteria of 
the following: (a) molecular weight ≤ 500, (b) XLOGP3 <3.5, (c) hydrogen bond acceptor ≤ 10 and (d) 
hydrogen bond donor ≤ 5. Therefore in this context, it was observed that the chemical compounds namely 
CID 74332343, CID 23520197, CID 5288446, CID 58763319, CID 86706411, CID 510181 had zero 
violation of the RO5. On the contrary molecules CID 20752846, CID 10346022 and CID 20752877 had no 
more than one violation (Mol. Wt. > 500) of the above criteria. Since all these analog molecules satisfy RO5, 
therefore, they were classified as virtual drug-like molecules. 
Pharmacokinetics assessment of the analogs: The critical pharmacokinetic properties of the analogs 
relating to its Gastro Intestinal (GI) absorption, Blood Brain Barrier (BBB) permeation, drug metabolism, and 
permeability glycoprotein activity are highlights in Table 4.  
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Table 4: The pharmacokinetics properties of the top ten best-fitted analogs of mPDF inhibitors   
 
Sl. 
No 
Molecule GI 
absorption 
BBB 
permeant 
CYP1A2 
inhibitor 
CYP2C19 
inhibitor 
CYP2D6 
inhibitor 
CYP3A4 
inhibitor 
CYP2C9 
inhibitor 
 
Pgp 
substrate 
1 CID 
23520197 
High No No No Yes Yes Yes Yes 
2 CID 
74332344 
High No No No No No No Yes 
3 CID 
5288446 
High No No No No No No No  
4 CID 
58763319 
High No No No No No No Yes 
5 CID 
86706411 
High No No No No No No Yes 
6 CID 
74332343 
High No No No No No No Yes 
7 CID 
20752846 
High No No No Yes Yes Yes Yes 
8 CID 
20752877 
High No No No No No Yes No 
9 CID 
10346022 
High No No No No No Yes Yes 
10 CID 
510181 
High No No No No No Yes Yes 
 
From the Table 4, it is observed that all the analogs have high gastrointestinal absorption capability and 
therefore can be easily translocated to the blood stream. Ideally, the chemical analog compound should target 
other parts of the human body except for the brain therefore preferably the analogs should not cross the BBB 
to avoid possible neurological side effects [21]. In the present study, all the screened analogs were predicted 
to be nonpermeable to BBB, therefore, it avoids the possible psychotropic side effects associated with 
non-neuroactive drugs permeable to BBB. Metabolic clearance of the drug from the body is an important 
pharmacokinetic property of any drug molecule. Therefore the roles of cytochromes P450 (CYPs) drug 
metabolizing enzymes are essential for the metabolism and clearance of the drug from the human system [22]. 
In this case, the ligands CID 20752846, CID 510181, CID 20752877 and CID 10346022 inhibits the members 
of cytochrome p450 family of oxidizing enzymes namely CYP2D6, CYP3A4 and CYP2C9 which play an 
important role in drug metabolism. Since the proper functioning of CYPs enzymes is essential for the 
metabolic clearance of the drug from the body. Therefore the inhibition of these enzymes by the analog 
molecules might result in increased bioavailability and the strong possibility of overdosing and eventually 
toxicity. However, the analogs CID 23520197, CID 74332344, CID 5288446, CID 58763319, CID 86706411 
and CID 74332343 are non-inhibitors of drug metabolizing enzymes, therefore, have good pharmacokinetic 
properties. P-glycoprotein (P-gp) is a transmembrane permeability glycoprotein that functions as a primary 
active efflux transporter. A number of important drugs are substrates to P-gp and that negatively affect their 
bioavailability and resistance is induced because of the effluxing nature of the protein. Therefore chemical 
compound which is non-substrate of P-gp protein is expected to overcome the poor bioavailability and 
multidrug resistance problems [23]. In this context, the derivative of galardin (CID 5288446) was predicted to 
be a non-substrate for P-gp protein thus negating the efflux mechanism of P-gp protein. Thereby the drug-like, 
lead molecule CID 5288446 may overcome the bioavailability and multi-drug resistance issues associated 
with anti-tuberculosis drugs.  
Molecular docking analysis of lead drug-like molecule and its parent compound: Molecular docking of 
both the parent compound (galardin) and the drug-like lead derivative molecule (CID 5288446) of galardin 
was performed against the crystal structure of mPDF using the very slow (accurate) docking protocol of 
iGEMDock2.1. The interaction of galardin and its analogs with mPDF protein was estimated using total 
5
  
binding, van der Waals interaction (VDW) and Hydrogen bonding interaction energy. The energy profiles 
along with the hydrogen bond forming residues are tabulated in Table 5. 
 
Table 5: Binding energies of galardin and its drug-like analog docked against the crystal structure of mPDF 
using accurate docking protocol of iGEMDOCK 
 
Sl. 
No. 
Ligand Total 
Energy 
VDW HBond 
1 
2 
Galardin 
CID 5288446 
-127.186 
142.01 
-107.735 
-96.17 
-19.4516 
-45.84 
 
 From the Table 5, it is evident that the analog CID 5288446 (142.01 kcal/mol) shows a higher total 
binding energy (affinity) for mPDF protein than its corresponding parent compound galardin (127.186 
kcal/mol). The van der Waals and hydrogen bond interaction energy of CID 5288446 was observed to be 
-96.17 kcal/mol and -45.84 kcal/mol, respectively. The hydrogen bonding interaction between the analog CID 
5288446 and mPDF protein was far better than its parent compound galardin. Therefore CID 5288446 can be 
considered as a better lead molecule since it interacts with mPDF with greater affinity and efficacy than its 
parent compound.  
Interaction analysis of screened ligand and its parental compound with mPDF protein: The most 
important factor in protein-ligand interaction is the Van der Waals force of interaction and hydrogen bonding 
as they play an important role in determining the binding efficacy and orientation of drug-like molecule to its 
targets receptor or protein. The interaction profile of galardin and its derivative CID 5288446 with mPDF is 
tabulated in Table 6. 
 
Table 6: The Hydrogen bond and van der Waals Interacting Residues of mPDF protein with the putative 
mPDF inhibitor (CID 5288446) and its parental compound galardin 
 
Protein 
Used 
Ligand Interacting 
Residue 
(Hydrogen 
Bond)  
 Hydrogen bond 
interaction  
energy 
(kcal/mol) 
Interacting 
Residue 
(Van der Waals) 
Vander walls 
interaction energy 
(kcal/mol) 
mPDF CID 5288446 
Analog of 
galardin 
GLN56 -4.6 GLY51 -5.7 
  LEU107 -7.0 GLY105 -10.4 
  HIS148 -8.8 CYS106 -4.9 
  GLU149 -7.0 LEU107 -8.7 
  HIS152 -3.5 HIS148 -11.6 
    PHE195 -17.4 
    HIS197 -6.0 
 
 
We observe from Table 5 that both hydrogen bonding and Van der Waals force of interaction profile of 
galardin as well as its derivative CID 5288446 are nearly similar. However, the efficacy of the interaction of 
the amino acids with the ligand in terms of energy is higher for CID 5288446 than its parental compound 
galardin. The hydrogen bond and Van der Waals force of interaction between the analog (CID 5288446) and 
mPDF protein is illustrated in Figure 1.  
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Figure 1: 2D representation of the hydrogen bonded and Van der Waals interactions of the putative inhibitor 
CID 5288446 (analog of galardin) with mPDF protein. The red dooted lines represent the Van der Waals force 
of interaction and the green colored dotted line represent the hydrogen bonded interaction between the ligand 
and protein. 
As illustrated in Figure 1 the residues HIS152 and GLU56 of mPDF protein displayed strong hydrogen 
bonding with oxgen atom attached to hydroxyl group of the analog with corresponding bond length of 2.96 Å 
and 3.03 Å. Additionally amino acids GLU56 and LEU107 of the target protein also forms a hydrogen bond 
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with the carbonyl oxygen atom of the analog with a bond legth of 3.33 and 2.82 Å, respectively. GLU149 and 
HIS197 on the other hand forms a hydrogen bond with the nitrogen atom attached to the amine group of 
analog molecuele (CID 5288446) with a bond length of 3.07 and 2.79 Å, respectively. Results suggest that 
hydroxyl, carbonyl and amine groups of the analog act as the major functional groups assisting in the binding 
process of the analog (CID 5288446) with mPDF protein. The presence of CID 5288446 molecule interacting 
with residues lying close to the active site residues H132EXXH136 might hinder the activity of the protein and 
thereby inhibiting the function of mPDF in Mycobacterium tuberculosis. Therefore it can be suggested that 
the analog CID 5288446 of galardin as shown in Figure 2 can be a good lead molecule against mPDF protein 
based upon it efficiency in binding the ligand binding domain of mPDF protein with higher efficacy. 
 
   
 
 
Figure 2: 2D structure of a putative mPDF inhibitor (CID 5288446) 
 
Biological activity and toxicity studies of drug-like molecule and its parent compound: PASS (Prediction 
of Activity Spectra for Substances) software was used to predict the biological activity and toxic properties of 
the drug-like analog molecule (CID 5288446) as well as its parental compound (galardin). The prediction is 
based upon the structure-activity relationships calculated from the experimental data of known compound and 
then compared with data of the studied compound. The PASS algorithm also estimates the probability of the 
studied compound to be active or inactive as depicted by Pa (probability to be active) and Pi (probability to be 
inactive). The estimated biological activity and possible toxic effects for galardin and its derivative (CID 
5288446) are tabulated in Table 7 and 8, respectively.  
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Table 7: Prediction of the biological activity of Galardin and its derivative (CID 5288446) based on the 
structure-activity relationship function of PASS software  
  
Sl. No. Ligand Pa Pi Activity  
1 CID 5288446 0.698 0.003 Metalloproteinase inhibitor 
2 Galardin  0.716 0.002 Metalloproteinase inhibitor 
 
Pa: Probability of chemical compound to be active 
Pi: Probability of the chemical compound to be inactive 
 
Table 8: Prediction of toxic effects associated with galardin and it derivative (CID 5288446) based on the 
structure of structure-activity relationship function of PASS software. 
 
Sl. No. Ligand Pa Pi Toxic effects 
1 CID 5288446  
(analog of Galardin) 
0.387 0.135 Edema 
0.296 0.191 Urinary retention 
0.269 0.248 Occult bleeding 
     
2 Galardin  
(Parent Compound) 
0.770 0,050 Edema 
0,766 0,055 Urinary retention 
0,683 0,154 Occult bleeding 
0,571 0,169 Necrosis 
0,531 0,158 Yawning 
0,672 0,239 Retroperitoneal fibrosis 
0,633 0,229 Visual acuity impairment 
 
Pa: Probability of chemical compound to be active 
Pi: Probability of the chemical compound to be inactive 
 
We observe that both the analog (CID 5288446) and it parental structure (galardin) show similar 
metalloproteinase inhibitor activity and the probability for them to be an active inhibitor is also more of less 
same as depicted in Table 7. The predicted metalloproteinase inhibiting activity of CID 5288446 can be found 
in a US patent (US2010178259) where the compound CID 5288446 is used as a matrix metalloproteinase 
inhibitor to reduce fibrosis in skin (https://pubchem.ncbi.nlm.nih.gov/compound/5288446#section=Top). 
Similarly, Galardin has been screened as an active compound as a metalloproteinase inhibitor in many 
bioassays namely AID-107338, 107348, 107358, 108007, 108308 and 108731 
(https://pubchem.ncbi.nlm.nih.gov/compound/132519#section=BioAssay-Results). As observed from Table 8 
the toxic effects of the analog (CID 5288446) are less as compared to its parental compound (galardin). 
Additionally, for galardin PASS predicts few more toxic effects namely necrosis, yawning, retroperitoneal 
fibrosis and visual acuity impairment. The profiling of the possible adverse or toxic effects by PASS is based 
on clinical manifestations, detected in a handy or even in a single patient. Therefore, it can be proposed that 
the derivative (CID 5288446) of galardin can be used as a lead molecule to inhibit the mPDF of MTB with 
minimum toxicity and higher efficacy. 
 
4. Conclusion: Based on results of oral bioavailability & pharmacokinetics properties, affinity for mPDF 
protein and structure-activity relationship & toxicity, it can be postulated that, 
(2R)-N’-hydroxy-N-[(2S)-3-(5H-indol-3-yl)-1-oxopropan-2-yl]-2-(2-methylpropyl) (CID 5288446) an analog 
of galardin can potentially prove to be better lead molecule than its parental compound in inhibiting the 
metalloproteinase activity of the mPDF protein in MTB. Therefore, identifying new therapeutic against MTB, 
which has been one of the prime motivating objectives considered while devising the study. Although the 
stability of the devised drug is yet to be tested computationally as well as impact in wetlab experimental 
studies.. The drug-like anlog CID 5288446 identified will aid in inhibiting activity of mPDF protein with 
minimum toxicity and higher efficacy. 
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